Archive for 'Recovery'

NIDAMED Helps Doctors Provide the Best in Medical Care

Washington, D.C. – The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, today unveiled its first comprehensive Physicians’ Outreach Initiative, NIDAMED, which gives medical professionals tools and resources to screen their patients for tobacco, alcohol, illicit, and nonmedical prescription drug use. The NIDAMED resources include an online screening tool, a companion quick reference guide, and a comprehensive resource guide for clinicians. The initiative stresses the importance of the patient-doctor relationship in identifying unhealthy behaviors before they evolve into life threatening conditions.

The NIDAMED tools – targeting primary care clinicians – were launched at a news conference at the National Press Club that featured NIDA Director Dr. Nora D. Volkow, Acting Director of the Office of National Drug Control Policy Ed Jurith, J.D., Sen. Carl Levin of Michigan, Acting Surgeon General Steven K. Galson, M.D., and representatives from the World Health Organization, the American Medical Association, and other organizations committed to helping patients who struggle with drug-related medical issues.

“Many patients do not discuss their drug use with their physicians, and do not receive treatment even when their drug abuse escalates,” said Dr. Volkow. “NIDAMED enables physicians to be the first line of defense against substance abuse and addiction and to increase awareness of the impact of substance use on a patient’s overall health.”

In 2007, an estimated 19.9 million Americans aged 12 or older (around 8 percent of the population) were current (past month) users of illegal drugs – nearly 1 in 5 of those 18 to 25 years old – and many more are current tobacco or binge alcohol users. The consequences of this drug use can be far-reaching – playing a role in the cause and progression of many medical disorders, including addiction. Yet only a fraction of people who need addiction treatment receive it.

“I have long worked with NIDA to increase access to effective treatment in the battle against addiction,” said Sen. Levin. “By encouraging physicians to consult with, screen and refer their patients who are in need of treatment, the NIDAMED initiative is a critical step towards achieving that goal. We must find ways to disseminate these important clinical tools, that can aid in mending lives and families, once torn asunder due to the scourge of addiction.”

The NIDAMED tools were developed because doctors are in a unique position to discuss drug-taking behaviors with their patients before they lead to serious medical problems. Research shows that screening, brief intervention, and referral to treatment by clinicians in general medical settings, can promote significant reductions in alcohol and tobacco use.

A growing body of literature also suggests potential reductions in illegal and nonmedical prescription drug use. Yet many primary care physicians express concern that they do not have the experience or diagnostic tools to identify drug use in their patients.

“Not only will these tools potentially help clinicians identify the use of drugs such as cocaine and heroin, they can also identify patients who are misusing prescription medications,” said Dr. Galson, a rear admiral in the U.S. Public Health Service. “In 2007, 16.3 million Americans age 12 and older had taken a prescription pain reliever, tranquilizer, stimulant, or sedative for nonmedical purposes at least once in the past year – behaviors that can lead to serious health problems, including addiction.”

“My doctor literally saved my life,” said Mink Rockmoore, a former Boston-area radio announcer who is a recovering heroin addict. “He worked hard to build my trust; he listened to my fears in a non-judgmental way; and he arranged for me to get both detox and treatment.”

NIDAMED’s screening tool was adapted from the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), developed, validated, and published by the World Health Organization (WHO) as an effective screening tool for identifying substance use. NIDA-modified ASSIST tools are specifically designed to fit into today’s busy clinical practices. Doctors can access the new tools at www.drugabuse.gov by clicking on the NIDAMED icon.

The online screening tool is an interactive Web site that guides clinicians through a short series of questions and, based on the patient’s responses, generates a substance involvement score that suggests the level of intervention needed. A physician can use this interactive tool during routine office visits. NIDAMED also includes an online resource guide with detailed instructions on how to implement the screening tool, discuss screening results, offer a brief intervention and make necessary referrals. In addition, a quick reference guide has been developed to serve as a prompt to medical professionals to initiate screening. This abbreviated guide provides a snapshot of the NIDA-modified ASSIST, briefly summarizing the questions, scoring and next steps.

Also included in the NIDAMED physician toolkit is a patient-tested postcard that encourages patients to “Tell Your Doctors About All the Drugs You Use” and offers Web links for further information. Doctors are encouraged to put the cards in their waiting rooms to be read by patients before their appointments.

NIDAMED was unveiled in conjunction with NIDA’s recently updated Principles of Drug Abuse Treatment: A Research Based Guide. This publication summarizes the 13 evidence-based principles of effective treatment, answers common questions, and describes types of treatment, providing examples of scientifically based and tested treatment components. The principles are based on three decades of scientific research and clinical practice that have yielded a variety of effective approaches to drug addiction treatment.

More information on all NIDAMED products and the Principles of Drug Abuse Treatment: A Research Based Guide can be found at www.drugabuse.gov/nidamed.



The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at www.drugabuse.gov. To order publications in English or Spanish, call NIDA’s new DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov.

The National Institutes of Health (NIH) – The Nation’s Medical Research Agency – includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


For more information about any item in this Release Contact:

Download PDF [104 KB]


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Wednesday, May 13, 2009. The U.S. government's official web portal
  • Share/Save/Bookmark
According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) National Survey on Drug Use and Health in 2006, 23.6 million persons aged 12 or older needed treatment for an illicit drug or alcohol abuse problem (9.6 percent of the persons aged 12 or older). Of these, only 2.5 million—10.8 percent of those who needed treatment—received it at a specialty facility.

SAMHSA also reports characteristics of admissions and discharges from substance abuse treatment facilities in their Treatment Episode Data Set (TEDS). According to TEDS, in 2006 there were nearly 1.8 million admissions for treatment of alcohol and drug abuse to facilities that report to State administrative data systems.1,2 Most admissions (40 percent) were for alcohol treatment. Heroin and other opiates accounted for the largest percentage of drug-related admissions (18 percent), followed by marijuana (16 percent).

By Drug: Admissions to Publicly Funded
Substance Abuse Treatment Programs, 2006


Percentage
of Admissions*
Substance
or Drug
21.9 Alcohol
17.8 Alcohol + another drug
16.1 Marijuana
13.7 Heroin
9.9 Smoked cocaine (crack)
8.7 Stimulants
4.2 Opiates (not heroin) **
4.0 Other-than-smoked cocaine (e.g., cocaine powder)
0.4 Tranquilizers
0.2 PCP
0.2 Sedatives
0.1 Hallucinogens
0.1 Inhalants
0.5 Other drugs
2.4 None reported

About 59 percent of admissions were White, 21 percent were African-American, and 14 percent were Hispanic or Latino. Another 2.3 percent were Alaska Native or American Indian and 1 percent were Asian/Pacific Islander. The remaining 2 percent fell into the “Other” category.

By Race: Admissions to Publicly Funded
Substance Abuse Treatment Programs, 2006

Percentage
of Admissions
Race/Ethinicity
59.4 White
21.3 African-American
14.0 Hispanic Origin
2.3 American Indian or Alaska Native
1.0 Asian/Pacific Islander
2.0 Other

The majority of patients entering treatment were 20–24 years old (14.4 percent), followed by those 25 to 29 (14 percent) and 40 to 44 (13.9 percent).

By Age Group: Admissions to Publicly Funded
Substance Abuse Treatment Programs, 2006


Percentage
of Admissions
Age Group
14.4 20 – 24
14.0 25 – 29
13.9 40 – 44
13.1 35 – 39
11.3 30 – 34
11.1 45 – 49
10.4 15 – 19
9.0 50 – 59
1.3 younger than 15
1.0 60 – 64
0.6 65 or older

For other information on treatment trends, visit the Substance Abuse and Mental Health Services Administration, Office of Applied Studies Web site at www.oas.samhsa.gov or visit the National Clearinghouse for Alcohol and Drug Information at www.health.org.

For information on treatment research findings, visit the NIDA web site at www.nida.nih.gov/DrugPages/Treatment.html.



1 Includes facilities that are licensed or certified by the State substance abuse agency to provide substance abuse treatment. In general, facilities that report data are those that receive State alcohol and/or drug agency funds for the provision of alcohol and/or drug treatment services.

2 Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights – 2006. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-40, DHHS Publication No. (SMA) 08-4313, Rockville, MD.


* May add up to more than 100 percent because of rounding.

** These drugs include codeine, hydrocodone, hydromorphone, meperidine, morphine, opium, oxycodone, pentazocine, propoxyphene, tramadol, and any other drug with morphine-like effects. Non-prescription use of methadone is not included.

Revised 6/08 This page has been accessed 1207581times since 11/5/99.

Recommended Reading

Other NIDA Web Sites


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Wednesday, May 6, 2009. The U.S. government's official web portal
  • Share/Save/Bookmark

Pursuing New Medications

NIDA Home > Publications > NIDA Notes > Vol. 19, No. 1 > Special Supplement
Developing Effective Addiction Treatments
Special Supplement
Vol. 19, No. 1 (April 2004)


Researcher

In recent years, people from all walks of life have sought treatment for addiction to powerful narcotic pain-relieving medications, such as OxyContin and Vicodin, that they have abused outside of a medical regimen. These medications share many properties with heroin, which currently ensnares more than a million people nationwide in the web of addiction. Those who become addicted to legal painkillers or street opiates now have a new medication to help them reclaim their lives. Approved by FDA in 2002, buprenorphine joins two other approved opiate treatment medications–methadone, used in long-term treatment, and the NIDA-developed opiate blocker naltrexone, used to help patients remain drug-free after they have stopped using opiates.

Buprenorphine is the first medication for opiate addiction treatment that can be prescribed by private physicians in offices and clinics. Use of this medication in mainstream medicine should help reduce the stigma still associated with drug abuse treatment, while encouraging more patients to seek treatment for addiction to heroin and other opiates. NIDA also is pursuing medications for cocaine and methamphetamine abuse and addiction, for which no medications are yet available. To fill this void, the Institute is applying the same scientific medications development methodologies that put effective opiate treatment medications into the hands of clinicians and their patients.

Researcher

On one research track, clinical researchers are screening medications previously approved to treat other disorders. In these small-scale trials, several agents have appeared to weaken the addictive cycle of drug-craving, drug-seeking, and drug-taking. Among them are amantadine (currently used for Parkinson’s disease), disulfiram (Antabuse), baclofen (an antispasticity agent), tiagabine and topiramate (antiepileptics), and modafinil (used in narcolepsy). Disulfiram and naltrexone, both effective in treating alcoholism, may fill a critical need for medications that can help cocaine-abusing individuals who also abuse alcohol. Propranolol, a medication used to lower blood pressure, may help substance abuse patients stay the course during the critical early days of treatment, by alleviating their unpleasant withdrawal symptoms. Researchers are now conducting larger, longer studies to confirm these encouraging results. Because the medications work by a variety of different mechanisms, some of which may complement each other, researchers also will examine whether they may be more effective in combination than alone. Some may also work optimally with specific behavioral therapies.

On another track, researchers in NIDA’s cocaine and methamphetamine treatment discovery programs are working to identify new chemical compounds whose pharmacological actions modulate the effects of psychostimulants on the brain and behavior. They already have shown that one compound that blocks a brain cannabinoid receptor can prevent animals from reinitiating cocaine use after exposure to drug-related cues and stressful events. Other compounds that curb the drug-induced flooding of the brain’s reward pathways with dopamine may be able to treat addiction to all abused drugs. Still other compounds counter psychostimulants’ ability to activate receptor molecules, nerve networks, and neurochemical mechanisms to create pleasure and craving.

NIDA Art CardNIDA uses art cards, displayed in restaurants and other public places, to warn smokers that nicotine, like other drugs, can be addictive.

Another NIDA initiative is focusing on new medications for treating nicotine addiction. Launched in the 1970s, NIDA’s basic research in this area provided the scientific basis for nicotine replacement therapies, such as the transdermal patch, that today help many patients overcome nicotine dependence. The Institute is now pursuing several approaches to medications that could intercept and neutralize nicotine, cocaine, and methamphetamine in the bloodstream before they can act in the brain. In one approach, vaccines containing the abused substance are linked with a larger carrier molecule and stimulate the body to produce antibodies to the drug. Another approach enhances the rate at which the body’s enzymes break down the drug molecules into inactive byproducts.

Identifying Effective Behavioral Therapies

Therapies that help drug abuse patients overcome erroneous thought patterns and behaviors that reinforce their abuse and addiction are critical in treating drug abuse and preventing its harmful consequences. Cognitive-behavioral therapies can stand alone as front-line interventions that help many patients stop using drugs and remain drug-free. And they can increase the effectiveness of treatment medications by boosting patients’ motivation to remain in treatment, take their medication as scheduled, and learn strategies to avoid relapse and lead drug-free lives. NIDA-supported research has demonstrated that combining medications, as available, with behavioral treatments is the best way to enhance success for most patients.

Man sitting on a couch

Over the last decade, NIDA’s Behavioral Therapies Development Program established a three-stage process to develop and introduce new behavioral approaches into clinical practice, similar to that required by the Food and Drug Administration to establish the safety and efficacy of medications. Building on research that suggests avenues for developing new therapies or refining existing ones, pilot studies explore the potential of each new or refined treatment. Those showing promise are then tested in research settings in small- and large-scale clinical trials. Finally, clinical trials can be done in community settings for those therapies that demonstrate therapeutic efficacy.

NIDA behavioral therapy researchers have designed several cognitive-behavioral therapies to help methamphetamine abusers. One innovative therapy gives patients a voucher each time they submit a drug-free urine sample. Vouchers may be exchanged for goods or services that provide pleasurable, legal alternatives to drug use or, as in methadone treatment programs, for special privileges, like reducing the number of required visits to a treatment clinic. Studies show that providing vouchers for drug-free urine tests can help patients stop cocaine and methamphetamine use and remain abstinent for extended periods. Variations of voucher-based therapies that use lower cost vouchers or involve family and other community resources in treatment can be matched to the resources of treatment programs and needs of cocaine-addicted individuals.

Ethnic FamilyFamily therapies tailored to the ethnicity or race of substance-abusing teens have proven successful.

In the last 10 years, behavioral treatments have demonstrated their potency in improving the health of diverse individuals with many types of drug abuse and other mental disorders. Proven treatments include individual cognitive-behavioral therapy, family therapies for Hispanic and African-American adolescent substance abusers, combination behavioral and medication therapies for adult smokers, and couples therapy for opiate-addicted men and women in methadone treatment programs. The benefits of many of these treatments endure long after treatment has ended. And with individual cognitive-behavioral therapy, the benefits appear to increase over time.

Volume 19, Number 1 (April 2004)

NIDA Notes graphic

Search NIDA Notes

About NIDA Notes

Free Subscription
to NIDA Notes

Volumes:

For additional information about NIDA Notes, send e-mail to Information@nida.nih.gov


NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment | Print Version


National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Friday, May 19, 2006. The U.S. government's official web portal
  • Share/Save/Bookmark

Many people do not understand why individuals become addicted to drugs or how drugs change the brain to foster compulsive drug abuse. They mistakenly view drug abuse and addiction as strictly a social problem and may characterize those who take drugs as morally weak. One very common belief is that drug abusers should be able to just stop taking drugs if they are only willing to change their behavior. What people often underestimate is the complexity of drug addiction—that it is a disease that impacts the brain and because of that, stopping drug abuse is not simply a matter of willpower. Through scientific advances we now know much more about how exactly drugs work in the brain, and we also know that drug addiction can be successfully treated to help people stop abusing drugs and resume their productive lives.

Drug abuse and addiction are a major burden to society. Estimates of the total overall costs of substance abuse in the United States—including health- and crime-related costs as well as losses in productivity—exceed half a trillion dollars annually. This includes approximately $181 billion for illicit drugs,1 $168 billion for tobacco,2 and $185 billion for alcohol.3 Staggering as these numbers are, however, they do not fully describe the breadth of deleterious public health—and safety—implications, which include family disintegration, loss of employment, failure in school, domestic violence, child abuse, and other crimes.

What is drug addiction?

Addiction is a chronic, often relapsing brain disease that causes compulsive drug seeking and use despite harmful consequences to the individual who is addicted and to those around them. Drug addiction is a brain disease because the abuse of drugs leads to changes in the structure and function of the brain. Although it is true that for most people the initial decision to take drugs is voluntary, over time the changes in the brain caused by repeated drug abuse can affect a person’s self control and ability to make sound decisions, and at the same time send intense impulses to take drugs.

It is because of these changes in the brain that it is so challenging for a person who is addicted to stop abusing drugs. Fortunately, there are treatments that help people to counteract addiction’s powerful disruptive effects and regain control. Research shows that combining addiction treatment medications, if available, with behavioral therapy is the best way to ensure success for most patients. Treatment approaches that are tailored to each patient’s drug abuse patterns and any co-occurring medical, psychiatric, and social problems can lead to sustained recovery and a life without drug abuse.

Similar to other chronic, relapsing diseases, such as diabetes, asthma, or heart disease, drug addiction can be managed successfully. And, as with other chronic diseases, it is not uncommon for a person to relapse and begin abusing drugs again. Relapse, however, does not signal failure—rather, it indicates that treatment should be reinstated, adjusted, or that alternate treatment is needed to help the individual regain control and recover.

What happens to your brain when you take drugs?

Drugs are chemicals that tap into the brain’s communication system and disrupt the way nerve cells normally send, receive, and process information. There are at least two ways that drugs are able to do this: (1) by imitating the brain’s natural chemical messengers, and/or (2) by overstimulating the “reward circuit” of the brain.

Some drugs, such as marijuana and heroin, have a similar structure to chemical messengers, called neurotransmitters, which are naturally produced by the brain. Because of this similarity, these drugs are able to “fool” the brain’s receptors and activate nerve cells to send abnormal messages.

Other drugs, such as cocaine or methamphetamine, can cause the nerve cells to release abnormally large amounts of natural neurotransmitters, or prevent the normal recycling of these brain chemicals, which is needed to shut off the signal between neurons. This disruption produces a greatly amplified message that ultimately disrupts normal communication patterns.

Nearly all drugs, directly or indirectly, target the brain’s reward system by flooding the circuit with dopamine. Dopamine is a neurotransmitter present in regions of the brain that control movement, emotion, motivation, and feelings of pleasure. The overstimulation of this system, which normally responds to natural behaviors that are linked to survival (eating, spending time with loved ones, etc.), produces euphoric effects in response to the drugs. This reaction sets in motion a pattern that “teaches” people to repeat the behavior of abusing drugs.

As a person continues to abuse drugs, the brain adapts to the overwhelming surges in dopamine by producing less dopamine or by reducing the number of dopamine receptors in the reward circuit. As a result, dopamine’s impact on the reward circuit is lessened, reducing the abuser’s ability to enjoy the drugs and the things that previously brought pleasure. This decrease compels those addicted to drugs to keep abusing drugs in order to attempt to bring their dopamine function back to normal. And, they may now require larger amounts of the drug than they first did to achieve the dopamine high—an effect known as tolerance.

Long-term abuse causes changes in other brain chemical systems and circuits as well. Glutamate is a neurotransmitter that influences the reward circuit and the ability to learn. When the optimal concentration of glutamate is altered by drug abuse, the brain attempts to compensate, which can impair cognitive function. Drugs of abuse facilitate nonconscious (conditioned) learning, which leads the user to experience uncontrollable cravings when they see a place or person they associate with the drug experience, even when the drug itself is not available. Brain imaging studies of drug-addicted individuals show changes in areas of the brain that are critical to judgment, decisionmaking, learning and memory, and behavior control. Together, these changes can drive an abuser to seek out and take drugs compulsively despite adverse consequences—in other words, to become addicted to drugs.

Why do some people become addicted, while others do not?

No single factor can predict whether or not a person will become addicted to drugs. Risk for addiction is influenced by a person’s biology, social environment, and age or stage of development. The more risk factors an individual has, the greater the chance that taking drugs can lead to addiction. For example:

  • Biology. The genes that people are born with––in combination with environmental influences––account for about half of their addiction vulnerability. Additionally, gender, ethnicity, and the presence of other mental disorders may influence risk for drug abuse and addiction.
  • Environment. A person’s environment includes many different influences––from family and friends to socioeconomic status and quality of life in general. Factors such as peer pressure, physical and sexual abuse, stress, and parental involvement can greatly influence the course of drug abuse and addiction in a person’s life.
  • Development. Genetic and environmental factors interact with critical developmental stages in a person’s life to affect addiction vulnerability, and adolescents experience a double challenge. Although taking drugs at any age can lead to addiction, the earlier that drug use begins, the more likely it is to progress to more serious abuse. And because adolescents’ brains are still developing in the areas that govern decisionmaking, judgment, and self-control, they are especially prone to risk-taking behaviors, including trying drugs of abuse.

Prevention is the Key

Drug addiction is a preventable disease. Results from NIDA-funded research have shown that prevention programs that involve families, schools, communities, and the media are effective in reducing drug abuse. Although many events and cultural factors affect drug abuse trends, when youths perceive drug abuse as harmful, they reduce their drug taking. It is necessary, therefore, to help youth and the general public to understand the risks of drug abuse, and for teachers, parents, and healthcare professionals to keep sending the message that drug addiction can be prevented if a person never abuses drugs.

1 Office of National Drug Control Policy. The Economic Costs of Drug Abuse in the United States: 1992-2002. Washington, DC: Executive Office of the President (Publication No. 207303), 2004.

2 Centers for Disease Control and Prevention. Annual Smoking–Attributable Mortality, Years of Potential Life Lost, and Productivity Losses — United States, 1997–2001. Morbidity and Mortality Weekly Report 54(25):625–628, July 1, 2005.

3 Harwood, H. Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data Report. Prepared by the Lewin Group for the National Institute on Alcohol Abuse and Alcoholism, 2000.

  • Share/Save/Bookmark

Next posts » Back to top